Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women
with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years
of tamoxifen & are switched to Aromasin® for completion of a total of 5 consecutive years of
adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial
waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since
then, there is currently lack of systematic collection and analysis for the efficacy and
safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Interventional
Study is being proposed to collect data systematically and to assess the efficacy and safety
of Aromasin® adjuvant setting in Chinese population.